Alessandro Pulsoni

Pubblicazioni

Titolo Pubblicato in Anno
Biopsia renale e diagnosi di linfoma a piccoli linfociti: nefropatia interstiziale acuta da infiltrazione linfocitaria in fase aleucemica 2016
Road traffic pollution and childhood leukemia: a nationwide case-control study in Italy ARCHIVES OF MEDICAL RESEARCH 2016
Splenic marginal zone lymphoma : Prognostic factors ,role of watch and wait policy ,and othert herapeutic approaches in the rituximab era EXPERT REVIEW OF HEMATOLOGY 2016
Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study JOURNAL OF CLINICAL ONCOLOGY 2016
Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era LEUKEMIA RESEARCH 2016
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study JOURNAL OF CLINICAL ONCOLOGY 2016
Infectious aetiology of marginal zone lymphoma and role of anti-infective therapy MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES 2016
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years CANCER MEDICINE 2016
A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma LEUKEMIA & LYMPHOMA 2016
Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia NEW ENGLAND JOURNAL OF MEDICINE 2015
Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: a retrospective cohort study LEUKEMIA RESEARCH 2015
Brentuximab vedotin in transplant-naïve relapsed/refractory hodgkin lymphoma: experience in 30 patients THE ONCOLOGIST 2015
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study LEUKEMIA & LYMPHOMA 2015
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study HAEMATOLOGICA 2015
The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma. The REFOLL study by the Fondazione Italiana Linfomi AMERICAN JOURNAL OF HEMATOLOGY 2015

Progetti di Ricerca

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma